Pseudobulbar affect: Prevalence and management

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 483-489

  Ahmed, Aiesha ^a   Simmons, Zachary ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Amyotrophic lateral sclerosis; Depression; Emotional lability; Multiple sclerosis; Pseudobulbar affect

Indexed keywords

DEXTROMETHORPHAN PLUS QUINIDINE; PLACEBO;

CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPHAGIA; EMOTIONAL DISORDER; FATIGUE; HEADACHE; HUMAN; NAUSEA; PATHOPHYSIOLOGY; PATIENT SELECTION; PSEUDOBULBAR AFFECT; PSYCHOLOGIC ASSESSMENT; REVIEW; RHINOPHARYNGITIS; TREATMENT OUTCOME;

EID: 84889814763     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S53906     Document Type: Review

References (39)

1. Parvizi J, Arciniegas DB, Bernardini GL, etal. Diagnosis and management of pathological laughter and crying. Mayo Clin Proc. 2006;81(11):1482-1486.
2. Parvizi J, Coburn KL, Shillcutt SD, Coffey CE, Lauterbach EC, Mendez MF. Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research. J Neuropsychiatry Clin Neurosci. 2009;21(1):75-87.
3. Colamonico J, Formella A, Bradley W. Pseudobulbar affect: burden of illness in the USA. Adv Ther. 2012;29(9):775-798.
4. Tateno A, Jorge RE, Robinson RG. Pathological laughing and crying following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2004;16(4):426-434.
5. Calvert T, Knapp P, House A. Psychological associations with emotionalism after stroke. J Neurol Neurosurg Psychiatry. 1998;65(6):928-929.
6. Müller U, Murai T, Bauer-Wittmund T, von Cramon DY. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Injury. 1999;13(10):805-811.
7. Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA. A self report measure of affective lability. J Neurol Neurosurg Psychiatry. 1997;63(1):89-93.
8. Sacco S, Sara M, Pistoia F, Conson M, Albertini G, Carolei A. Management of pathologic laughter and crying in patients with locked-in syndrome: a report of 4 cases. Arch Phys Med Rehabil. 2008;89(4): 775-778.
9. Cummings JL, Arciniegas DB, Brooks BR, etal. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr. 2006;11(6):1-7.
10. Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand. 1989;80(2):114-117.
11. McCullagh S, Moore M, Gawel M, Feinstein A. Pathological laughing and crying in amyotrophic lateral sclerosis: an association with prefrontal cognitive dysfunction. J Neurol Sci. 1999;169(12):4348.
12. Miller RG, Jackson CE, Kasarskis EJ, etal. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227-1233.
13. Strowd RE, Cartwright MS, Okun MS, Haq I, Siddiqui MS. Pseudobulbar affect: prevalence and quality of life impact in movement disorders. J Neurol. 2010;257(8):1382-1387.
14. Miller A, Pratt H, Schiffer RB. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother. 2011;11(7):1077-1088.
15. Work SS, Colamonico JA, Bradley WG, Kaye RE. Pseudobulbar affect: an under-recognized and under-treated neurological disorder. Adv Ther. 2011;28(7):586-601.
16. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain. 1998;121(Pt 4):561-579.
17. Parvizi J, Joseph J, Press DZ, Schmahmann JD. Pathological laughter and crying in patients with multiple system atrophy-cerebellar type. Mov Disord. 2007;22(6):798-803.
18. Haiman G, Pratt H, Miller A. Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect. J Neurol Sci. 2008;271(1-2):137-147.
19. Holtzman T, Rajapaksa T, Mostofi A, Edgley SA. Different responses of rat cerebellar Purkinje cells and Golgi cells evoked by widespread convergent sensory inputs. J Physiol. 2006;574(Pt 2):491-507.
20. Barmack NH, Yakhnitsa V. Functions of interneurons in mouse cerebellum. J Neurosci. 2008;28(5):1140-1152.
21. House A, Dennis M, Molyneux A, Warlow C, Hawton K. Emotionalism after stroke. BMJ. 1989;298(6679):991-994.
22. Rosen HJ, Cummings J. A real reason for patients with pseudobulbar affect to smile. Ann Neurol. 2007;61(2):92-96.
23. Morris PL, Robinson G, Raphael B. Emotional lability after stroke. Aust N Z J Psychiatry. 1993;27(4):601-605.
24. Pioro EP. Current concepts in the pharmacotherapy of pseudobulbar affect. Drugs. 2011;71(9):1193-1207.
25. Poeck K. Pathophysiology of emotional disorders associated with brain damage. In: Vinken PJ, Bruyn GW, editors. Handbook of Clinical Neurology. Amsterdam: North Holland Publishing; 1969;3: 343-367.
26. Smith RA, Berg JE, Pope LE, Callahan JD, Wynn D, Thisted RA. Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler. 2004;10(6):679-685.
27. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry. 1993;150(2):286-293.
28. Udaka F, Yamao S, Nagata H, Nakamura S, Kameyama M. Pathologic laughing and crying treated with levodopa. Arch Neurol. 1984;41(10):1095-1096.
29. Werling LL, Keller A, Frank JG, Nuwayhid SJ. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol. 2007;207(2):248-257.
30. Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K. Fluoxetine improves emotional incontinence. Brain Inj. 1992;6(3):267-270.
31. Sloan RL, Brown KW, Pentland B. Fluoxetine as a treatment for emotional lability after brain injury. Brain Inj. 1992;6(4):315-319.
32. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol. 1996;19(6):532-535.
33. Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatr Scand. 1998;98(6):455-458.
34. Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R. Sertraline in stroke-associated lability of mood. Int J Geriatr Psychiatry. 1999;14(8):681-685.
35. Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke. 2006;37(1):156-161.
36. Panitch HS, Thisted RA, Smith RA, etal. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59(5):780-787.
37. Pioro EP, Brooks BR, Cummings J, etal. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693-702.
38. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58(1):19-36.
39. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med. 1985;312(23):1480-1482.